MAM
AKRO

Martingale Asset Management’s Akero Therapeutics AKRO Stock Holding History

Martingale Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,915
Closed -$328K – 773
2025
Q3 		$328K Buy
+6,915
New +$335K 0.01% 677
2023
Q4 		– Sell
-21,260
Closed -$1.08M – 784
2023
Q3 		$1.08M Buy
21,260
+16,946
+393% +$789K 0.02% 416
2023
Q2 		$201K Buy
+4,314
New +$198K ﹤0.01% 763
2022
Q3 		– Sell
-15,316
Closed -$145K – 820
2022
Q2 		$145K Sell
15,316
-10,895
-42% -$114K ﹤0.01% 818
2022
Q1 		$373K Buy
26,211
+2,100
+9% +$36.8K 0.01% 694
2021
Q4 		$511K Buy
24,111
+1,200
+5% +$26.6K 0.01% 643
2021
Q3 		$513K Buy
+22,911
New +$519K 0.01% 665
2021
Q2 		– Sell
-7,106
Closed -$207K – 822
2021
Q1 		$207K Buy
+7,106
New +$215K ﹤0.01% 817
2020
Q4 		– Sell
-26,105
Closed -$804K – 869
2020
Q3 		$804K Buy
+26,105
New +$912K 0.01% 694

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Martingale Asset Management's AKRO Position: Q4 2025 in Review

Martingale Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 6,915 shares — an estimated $328K sold.

Martingale Asset Management first reported a position in AKRO in Q3 2020 and held it in 9 quarters. The position peaked at $1.08M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Martingale Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Martingale Asset Management sold 6,915 Akero Therapeutics shares in Q4 2025, an estimated $328K.
  • Martingale Asset Management first reported a position in Akero Therapeutics in Q3 2020 and held it in 9 quarters.
  • Martingale Asset Management's Akero Therapeutics position peaked at $1.08M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Martingale Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.